KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
Go back to KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
September 30, 2015 2:19 PM EDT
RBC Capital analyst Randall Stanicky reiterated an Outperform rating and $22 price target on Kempharm (NASDAQ: KMPH) as new KP201 abuse-deterrent data add further support to product differentiation.
Stanicky commented, "This morning, KMPH released results of three tamper studies which showed KP201 holding up... More
September 30, 2015 7:33 AM EDT
KemPharm (NASDAQ: KMPH) reported positive results from three distinct studies designed to evaluate the tamper-resistant properties of its lead opioid prodrug KP201/APAP, KemPharm's prodrug of hydrocodone in combination with acetaminophen (APAP) compared to a generic hydrocodone bitartrate/APAP product (HB/APAP). The studies were designed based on feedback from the U.S. Food and Drug Administration (FDA). KemPharm believes that, together with the positive data from KemPharm's previous human abuse liability trials, these results may support FDA Category 1 abuse-deterrent language in the KP201/APAP product label, if approved by the... More
